Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12435931 | 0.90 | KDM4E (0.40) | KDM4EHTTLMNAMAPTALDH1A1 | |
| SCHEMBL17507479 | 0.89 | LMNA (0.47) | KDM4EHTTLMNAMAPTKMT2A | |
| SCHEMBL12435917 | 0.86 | MAPT (0.44) | KDM4EHTTLMNAMAPTALDH1A1 | |
| SCHEMBL12435929 | 0.85 | KDM4E (0.44) | KDM4EHTTLMNAMAPTALDH1A1 | |
| SCHEMBL12435920 | 0.84 | ATM (0.49) | HTTLMNAMAPTALDH1A1MAPK1 | |
| SCHEMBL12435911 | 0.84 | KDM4E (0.45) | KDM4EHTTLMNAMAPTALDH1A1 | |
| SCHEMBL12435921 | 0.83 | LMNA (0.43) | KDM4EHTTLMNAMAPTALDH1A1 | |
| SCHEMBL12435933 | 0.83 | KDM4E (0.44) | KDM4EHTTLMNAMAPTALDH1A1 | |
| SCHEMBL17507531 | 0.78 | LMNA (0.47) | KDM4EHTTLMNAMAPTKMT2A | |
| SCHEMBL12435907 | 0.76 | TUBB4A (0.49) | KDM4EHTTLMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178108-A1 | Group of amino substituted benzoyl derivatives and their preparation and their use | Institute of Medicinal Biotechnology Academy of Medical Science (CN) | 2011-07-21 | — | — | US | disclosed |
| US-20110178108-A1 | Group of amino substituted benzoyl derivatives and their preparation and their use | Institute of Medicinal Biotechnology Academy of Medical Science (CN) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178108-A1 | Group of amino substituted benzoyl derivatives and their preparation and their use | CUL3, APOBEC3G, BRPF3 | KDM4E 368/4885HTT 1248/4885LMNA 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.